Treatment of Biochemical Recurrence After Prostatectomy and Radiation
For patients with biochemical recurrence after both prostatectomy and subsequent salvage radiation therapy, androgen deprivation therapy (ADT) is the primary treatment option, with consideration of intermittent ADT to reduce side effects, though early hormonal therapy should be reserved for high-risk patients with PSA doubling time <12 months. 1, 2
Understanding Your Clinical Situation
This scenario represents a challenging situation where the patient has exhausted local treatment options. After prostatectomy, salvage radiation was already administered, and now PSA is rising again—indicating either local persistence or distant micrometastatic disease that cannot be addressed with further local therapy.
Risk Stratification is Critical
Before initiating treatment, you must stratify risk based on:
- PSA doubling time (PSADT): <12 months indicates high-risk disease requiring more aggressive intervention 3, 1
- Gleason score: ≥7 (particularly Grade Group 4-5) indicates worse prognosis 4
- Time to recurrence: Shorter intervals suggest more aggressive biology
- Absolute PSA level: Higher values correlate with metastatic risk 3
Imaging Evaluation
Obtain restaging imaging to rule out metastatic disease before committing to systemic therapy 3:
- Conventional imaging (CT, MRI, bone scan) remains standard, though sensitivity is limited at low PSA levels 3
- Consider advanced imaging (PSMA PET) if available, particularly when PSADT <12 months or PSA >1.0 ng/mL, as this may detect oligometastatic disease amenable to metastasis-directed therapy 5, 6
- If imaging shows no metastases, you're dealing with biochemical recurrence without radiographic disease
Treatment Algorithm
For High-Risk Features (PSADT <12 months, Gleason ≥8, PSA >50 ng/mL):
Initiate ADT promptly 1, 2. These patients have demonstrated aggressive biology by recurring after both surgery and radiation, and delaying systemic therapy risks progression to symptomatic metastatic disease.
For Lower-Risk Features (PSADT ≥12 months, lower Gleason scores):
Consider observation with close PSA monitoring 1, 2. The evidence shows that even in higher-risk patients, delaying ADT until metastases appear does not significantly impact survival, though it does delay time to clinical metastases 2. For truly low-risk biochemical recurrence, many patients will have prolonged survival even without immediate intervention.
ADT Administration Strategy:
Use intermittent ADT rather than continuous therapy 1, 2:
- Start ADT when PSA reaches a predetermined threshold (typically >3-5 ng/mL after radiation failure) 2
- Continue until PSA suppression to nadir (ideally <0.2 ng/mL)
- Stop ADT and monitor PSA every 3 months
- Restart when PSA rises to the same threshold
- This approach reduces side effects (hot flashes, sexual dysfunction, metabolic complications, bone loss) while maintaining equivalent survival compared to continuous therapy 2
Important Caveats and Pitfalls
Do not rush to ADT in asymptomatic patients with favorable kinetics. The guidelines explicitly state that early hormonal therapy is not routinely advised for PSA relapse after local treatments unless high-risk features are present 1, 2. Many patients will live for years with slowly rising PSA without clinical progression.
Avoid experimental salvage local therapies (HIFU, cryotherapy, additional focal therapy) in this setting—these should only be offered within clinical trials 2. After both surgery and radiation, the prostate bed has been extensively treated, and further local therapy carries significant toxicity without proven benefit.
Counsel patients extensively about ADT side effects before initiation 1. These include cardiovascular risks, metabolic syndrome, osteoporosis, cognitive changes, and profound impact on quality of life. The decision to start ADT should be shared with the patient, weighing the uncertain survival benefit against definite quality-of-life impacts.
When to Consider Novel Therapies
Androgen receptor pathway inhibitors (ARPIs) combined with ADT are emerging as options for very high-risk biochemical recurrence, though this represents an evolving area 5, 7, 8. Current evidence primarily supports ARPIs in metastatic disease, but ongoing trials are evaluating their role in high-risk non-metastatic biochemical recurrence. This should be discussed in multidisciplinary tumor board for patients with PSADT <6 months or other very high-risk features.
Monitoring Strategy
- PSA every 3-4 months during observation or off-treatment periods 3
- Repeat imaging if PSA velocity accelerates or absolute PSA exceeds thresholds where conventional imaging becomes useful (typically >10-20 ng/mL for bone scan, >5-10 ng/mL for PSMA PET) 3
- Clinical evaluation for symptoms of metastatic disease (bone pain, weight loss, neurologic symptoms)
The key principle is that after exhausting local therapies, you're managing a systemic disease with palliative intent, and the goal shifts from cure to maximizing quality-adjusted survival.